Failure to over express MHC-CLASS-1 on muscle biopsy in a case of amyopathic juvenile dermatomyositis

Clinical and Experimental Rheumatology

Volumn 25, Issue 1, 2007, Pages 96-98

  McCann, Lisa J ^a   Li, Charles K C ^b   Varsani, Hemlata ^b   Wedderburn, Lucy R ^b   Pilkington, Clarissa A ^b  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Amyopathic dermatomyositis; Dermatomyositis sine myositis; Inflammatory myopathy; Juvenile; MHC class 1

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; PREDNISOLONE;

ARTICLE; CASE REPORT; CHILDHOOD DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; DERMATOMYOSITIS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LOW DRUG DOSE; MUSCLE BIOPSY; MYOSITIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCHOOL CHILD; SCORING SYSTEM; SKIN BIOPSY; SYMPTOM; TREATMENT DURATION;

BIOPSY; CHILD; DERMATOMYOSITIS; FEMALE; GENES, MHC CLASS I; HLA ANTIGENS; HUMANS; MUSCLE WEAKNESS; MUSCLE, SKELETAL;

EID: 33947585183     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. LI CK, VARSANI H, HOLTON JL, GAO B, WOO P, WEDDERBURN LR: MHC Class I over expression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31: 605-9.
2. LOVELL DJ, LINDSLEY CB, RENNEBOHM RM et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999; 42: 2213-9.
3. MILLER LC, MICHAEL AF, BAXTER TL, KIM Y: Quantitative muscle testing in childhood dermatomyositis. Arch Phys Med Rehabil 1988; 69: 610-3.
4. FELDMAN BM, YLING-CAMPOS A, LUY L, STEVENS D, SILVERMAN ED, LAXER RM: Measuring disability in juvenile dermatomyositis: validity of the childhood health assessment questionnaire. J Rheumatol 1995; 22: 326-31.
5. RIDER LG, FELDMAN BM, PEREZ MD et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997; 40: 1976-83.
6. PLAMONDON S, DENT PB: Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol 2000; 27: 2031-4.
7. EUWER RL, SONTHEIMER RD: Amyopathic dermatomyositis: a review. J Invest Dermatol 1993; 100: 124S-7S.
8. ROCKERBIE NR, WOO TY, CALLEN JP, GIUSTINA T: Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 1989; 20: 629-32.
9. EISENSTEIN DM, PALLER AS, PACHMAN LM: Juvenile dermatomyositis presenting with rash alone. Pediatrics 1997; 100 (3 Pt 1): 391-2.
10. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
11. EUWER RL, SONTHEIMER RD: Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991; 24 (6 Pt 1): 959-66.
12. COSNES A, AMAUDRIC F, GHERARDI R et al.: Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995; 131: 1381-5.
13. MULLER SA, WINKELMANN RK, BRUNSTING LA: Calcinosis in Dermatomyositis. Arch Dermatol 1959; 79: 95-9.
14. BANKER BQ: Dermatomyostis of childhood, ultrastructural alterations of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol 1975; 34: 46-75.
15. KARPATI G, POULIOT Y, CARPENTER S: Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23: 64-72.